Neuronetics, a medtech company focused on neurohealth disorders, today announced the FDA clearance of its NeuroStar Advanced Therapy for use as an adjust for the treatment of major depressive disorder ...

MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of ...

Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics ...

A Malvern company says its non-drug treatment for depression continues to gain acceptance. Neuronetics Inc. announced Wednesday the outcomes registry for its NeuroStar Advanced Therapy treatment for ...

NEW YORK, May 6, 2014 – Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

Q1 2026 earnings call recap: revenue, guidance, cash runway, cost cuts, and NeuroStar pilots—get the key insights and take action.

MALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for ...

MALVERN, Pa., May 5, 2018 /PRNewswire/ -- NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced today that more than 1.7 million treatments have ...

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...